NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totalling 48,500 shares, a decrease of 92.5% from the May 31st total of 647,600 shares. Based on an average trading volume of 301,400 shares, the days-to-cover ratio is currently 0.2 days.

NovaBay Pharmaceuticals Trading Down 9.4 %

Shares of NYSEAMERICAN:NBY opened at $2.21 on Friday. NovaBay Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $44.80. The company has a market cap of $9.30 million, a price-to-earnings ratio of -0.22 and a beta of 2.82.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 146.20% and a negative net margin of 79.70%. The business had revenue of $2.63 million for the quarter. Equities analysts expect that NovaBay Pharmaceuticals will post -2.54 earnings per share for the current fiscal year.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.